Is Achieve Life Sciences profitable?

Achieve Life Sciences is not currently profitable: it reported a net loss of $52.0M over the trailing twelve months.

What is Achieve Life Sciences's earnings per share?

Achieve Life Sciences's diluted EPS over the trailing twelve months is $-1.10.

Where does Achieve Life Sciences's income statement data come from?

Every line is extracted from Achieve Life Sciences's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.

Achieve Life Sciences ACHV Income Statement

Income Statement Balance Sheet Cash Flow Ratios Segments

Quarterly Annual TTM

YoY QoQ

Simplified Detailed

	Q1 '26	Q4 '25	Q3 '25	Q2 '25	Q1 '25
Compensation and benefits	-$685K-153%	$1.3M-44.4%	$2.34M-19.0%	$2.89M+29.4%	$2.23M+79.6%
Occupancy and equipment	$32K+129%	$14K-44.0%	$25K-16.7%	$30K-3.2%	$31K+138%
Depreciation and amortization	$57K0.0%	$57K+5.6%	$54K-1.8%	$55K-11.3%	$62K+6.9%
Other operating expenses	——	-0.5%—	——	——	——
Total costs & expenses	$10.46M-29.0%	$14.73M+0.3%	$14.69M+16.9%	$12.56M-2.6%	$12.89M+5.8%
Interest expense	$274K+9.2%	$251K+30.7%	$192K+0.5%	$191K+3.2%	$185K-6.1%
Interest income	$297K-30.4%	$427K-22.9%	$554K+189%	$192K-40.4%	$322K-33.2%
Other income (expense), net	$295K+328%	$69K-72.5%	$251K+262%	-$155K-331%	$67K+139%
Income tax expense	——	0%—	——	——	——
Net income	-$10.17M+30.7%	-$14.66M-1.5%	-$14.44M-13.5%	-$12.72M+0.8%	-$12.83M-3.8%
Diluted earnings per share	-$0.19+26.9%	-$0.26+7.1%	-$0.28+24.3%	-$0.370.0%	-$0.37-2.8%
Basic earnings per share	-$0.19+26.9%	-$0.26+7.1%	-$0.28+24.3%	-$0.370.0%	-$0.37-2.8%
Weighted-average shares, diluted	53.4M+22.5%	43.6M-14.5%	51M+47.1%	34.7M0.0%	34.7M+8.2%
Weighted-average shares, basic	53.4M+22.5%	43.6M-14.5%	51M+47.1%	34.7M0.0%	34.7M+8.2%
Share-based compensation expense related to employee stock plans	-$685K-153%	$1.3M-44.4%	$2.34M-19.0%	$2.89M+29.4%	$2.23M+79.6%
Amortization Of Financing Costs	$12K+9.1%	$11K-15.4%	$13K-7.1%	$14K0.0%	$14K0.0%
Amortization of capitalized software and acquired intangible assets	$100K—	——	$100K0.0%	$100K0.0%	$100K—
Stock options excluded as their inclusion would be anti-dilutive (in shares)	26.6M-100.0%	24.4T—	——	——	22.7M-100.0%
Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1	-$285K-350%	$114K+7.5%	$106K+9.3%	$97K+6.6%	$91K-79.8%
Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Period Increase (Decrease), Including Exchange Rate Effect and Discontinued Operation	$7.36M—	——	——	$38.86M+14,675%	$263K—
Comprehensive Income (Loss), Net of Tax, Attributable to Parent	-$10.18M+30.6%	-$14.66M-1.6%	-$14.44M-13.5%	-$12.72M+1.0%	-$12.85M-3.6%
Effect of currency exchange rate changes on cash, cash equivalents, and restricted cash	——	$4K—	——	——	-$2K—
Effective tax rates	——	$0—	$0—	$0—	$0—
Income taxes at U.S. statutory rate of 21%	——	21%—	——	——	——
Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent	——	-19.9%—	——	——	——
Effective Income Tax Rate Reconciliation Change In Enacted Tax Rate	——	0%—	——	——	——
Effect of cross-border tax laws	——	0%—	——	——	——
Other	——	-$00.0%	-$00.0%	-$00.0%	-$0+28.6%
Share-based compensation	——	-2%—	——	——	——
State income taxes – net of federal income tax benefit	——	0%—	——	——	——
Changes in unrecognized tax benefits	——	0%—	——	——	——
Effective Income Tax Rate Reconciliation Tax Credits Research	——	-1.5%—	——	——	——
Effective Income Tax Rate Reconciliation, Tax Credit, Other, Percent	——	0%—	——	——	——
Future Income Tax Rate Assumed For Deferred Tax Calculations	——	21%—	——	——	——
Impairment of intangible assets	$0—	$0—	$0—	$0—	$0—
Income Loss From Continuing Operations Before Income Taxes Domestic	——	-$13.55M0.0%	-$13.55M0.0%	-$13.55M0.0%	-$13.55M-37.1%
Income Loss From Continuing Operations Before Income Taxes Foreign	——	-$114K0.0%	-$114K0.0%	-$114K0.0%	-$114K-54.6%
Federal taxes	——	$0—	$0—	$0—	$0—
Foreign	——	$0—	$0—	$0—	$0—
State taxes	——	$0—	$0—	$0—	$0—
Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount	——	$2.72M0.0%	$2.72M0.0%	$2.72M0.0%	$2.72M+27.4%
Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount	——	-$2.87M0.0%	-$2.87M0.0%	-$2.87M0.0%	-$2.87M-37.2%
Effective Income Tax Rate Reconciliation, Nondeductible Expense, Other, Amount	——	$66.25K0.0%	$66.25K0.0%	$66.25K0.0%	$66.25K-9.6%
Share-based compensation	——	$269.25K0.0%	$269.25K0.0%	$269.25K0.0%	$269.25K+76.6%
Effective Income Tax Rate Reconciliation, Other Adjustments, Amount	——	$4.25K0.0%	$4.25K0.0%	$4.25K0.0%	$4.25K+139%
Effective Income Tax Rate Reconciliation, Tax Credit, Research, Amount	——	$209.75K0.0%	$209.75K0.0%	$209.75K0.0%	$209.75K-22.6%
Income Taxes Paid, Net	——	$0—	$0—	$0—	$0—
Accrued compensation and employee benefits	$261K+151%	-$510K—	——	——	-$2.06M-401%
Increase Decrease In Lease Obligations	——	-$1K—	——	——	-$1K—
Indemnification Expense	$0—	$0—	$0—	$0—	$0—
Cash Provided by (Used in) Financing Activity, Including Discontinued Operation	$21K-99.7%	$6.26M+54.9%	$4.04M—	——	——
Cash Provided by (Used in) Investing Activity, Including Discontinued Operation	$14.28M+1,914%	$709K—	——	$6.7M-41.0%	$11.35M+310%
Cash Provided by (Used in) Operating Activity, Including Discontinued Operation	-$6.93M+61.4%	-$17.98M-58.7%	-$11.33M-24.9%	-$9.07M+18.2%	-$11.09M-20.7%
Number of operating segments	——	0.30.0%	0.30.0%	0.30.0%	0.30.0%
Occupancy and Related Charges	$32K+129%	$14K-44.0%	$25K-16.7%	$30K-3.2%	$31K+138%
Operating Lease Payments	$15K0.0%	$15K+7.1%	$14K+7.7%	$13K0.0%	$13K+8.3%
Net unrealized debt securities gains (losses), net of tax	-$8K—	$0-100%	$6K+300%	-$3K+88.0%	-$25K—
Other comprehensive income (loss)	-$8K—	$0-100%	$6K+300%	-$3K+88.0%	-$25K—
Other income, net (Note 6)	-$13K—	——	-$5K+91.5%	-$59K-381%	$21K+520%
Payments On Loss On Disposal Of Property And Equipment	——	$2500.0%	$2500.0%	$2500.0%	$250—
Payments to Acquire Marketable Securities	$1.16M—	——	$15.4M+1,617%	$897K-73.3%	$3.36M—
Percentage Of Voting Power	50%0.0%	50%—	——	——	50%0.0%
Proceeds From Exercise Of Overallotment Option Net Of Issuance Costs	——	$1M0.0%	$1M0.0%	$1M0.0%	$1M—
Proceeds From Realized Gain On Investments	——	$1K0.0%	$1K0.0%	$1K0.0%	$1K—
Proceeds from maturities of marketable securities	$15.43M—	——	$2.75M-63.8%	$7.6M-48.4%	$14.72M—
Proceeds From Warrant Exercises	$21K-98.3%	$1.27M—	——	——	——
Receipt Of SVB Convertible Term Loan Second Tranche	——	$1.25M0.0%	$1.25M0.0%	$1.25M0.0%	$1.25M—
Stock-based compensation	-$685K-153%	$1.3M-44.4%	$2.34M-19.0%	$2.89M+29.4%	$2.23M+79.6%
Expected volatility	76.6%-3.1%	79.7%—	——	——	78.9%-8.5%
Weighted-average grant date fair value of stock options (in dollars per share)	——	$3.81—	——	——	——
Granted (in shares)	2.3M+149%	929.5K—	——	——	124.5K-81.6%
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Forfeiture Rate	0%—	0%—	——	——	0%—
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period	69.6K+322%	16.5K—	——	——	——
Risk-free rate	3.9%0.0%	3.9%—	——	——	4.6%+0.6%
Weighted-average dividend yield	0%—	0%—	——	——	0%—
Intrinsic value of stock options exercised	——	$0—	$0—	$0—	$0—
Options canceled (in dollars per share)	$5.37-16.9%	$6.46—	——	——	——
Granted (in shares)	$4.36+14.4%	$3.81—	——	——	$3.30-27.3%
Shares Issued On Exercise Of Warrants Value	$21K—	——	$120K—	——	——
Unrecognized Tax Benefits Increases Decrease Resulting From Prior Period Tax Positions	——	$0—	$0—	$0—	$0—
Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount	——	$2.15M0.0%	$2.15M0.0%	$2.15M0.0%	$2.15M0.0%

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Questions, answered.

Is Achieve Life Sciences profitable?: Achieve Life Sciences is not currently profitable: it reported a net loss of $52.0M over the trailing twelve months.
What is Achieve Life Sciences's earnings per share?: Achieve Life Sciences's diluted EPS over the trailing twelve months is $-1.10.
Where does Achieve Life Sciences's income statement data come from?: Every line is extracted from Achieve Life Sciences's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.